Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies

Zachary Brennan

Senior Editor

When bluebird bio’s gene therapy to treat beta thalassemia won European approval in 2019, the nearly $2 million per patient price tag for the potential …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Even FDA's Pe­ter Marks is wor­ried about the com­mer­cial vi­a­bil­i­ty of gene and cell ther­a­pies

Senior Editor

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies